0000000000201613

AUTHOR

Georgios Schoretsanitis

0000-0002-3851-4117

showing 8 related works from this author

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis.

2022

Abstract Objective Neurological correlates of impaired insight in non-affective psychosis remain unclear. This study aimed to review and meta-analyze the studies assessing the grey matter volumetric correlates of impaired insight in non-affective psychosis. Methods This study consisted of a systematic review of 23 studies, and a meta-analysis with SDM-PSI of the 11 studies that were whole-brain and reported maps or peaks of correlation of studies investigating the grey matter volumetric correlates of insight assessments of non-affective psychosis, PubMed and OVID datasets were independently reviewed for articles reporting neuroimaging correlates of insight in non-affective psychosis. Qualit…

PsychosisPrecuneusBrainNeuroimaging610 Medicine & healthGeneral MedicineGrey mattermedicine.diseaseMagnetic Resonance ImagingCorrelationPsychiatry and Mental healthSuperior temporal gyrusmedicine.anatomical_structurePsychotic DisordersNeuroimaging10054 Clinic for Psychiatry Psychotherapy and PsychosomaticsMeta-analysismedicineHumansGeneral Earth and Planetary SciencesGray MatterPsychologyInsulaGeneral Environmental ScienceClinical psychologyRevista de psiquiatria y salud mental
researchProduct

Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis

2021

Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20–30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ⩾30 kg/m2, n=162) and with low body mass index values (CLZlow, body mass index <20 kg/m2, n=27). Comparisons of plasma and dose-adjusted plasma concentrations (C/D) of clozapine…

AdultMaleBiological AvailabilityPharmacologyBody weightBody Mass IndexYoung Adult03 medical and health sciencesSex Factors0302 clinical medicinePharmacokineticsmedicineHumansTissue DistributionPharmacology (medical)ObesityClozapineClozapineAgedRetrospective StudiesA determinantAged 80 and overPharmacologymedicine.diagnostic_testbusiness.industryBody WeightMiddle Agedmedicine.diseaseObesity030227 psychiatryPsychiatry and Mental healthAdipose TissueLiverTherapeutic drug monitoringPlasma concentrationFemaleDrug MonitoringbusinessBody mass index030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Psychopharmacology
researchProduct

A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adul…

2019

Introduction: This article comprehensively reviews the clinical utility of the serum clozapine/norclozapine (CLO/NCLO) ratio. Areas covered: Fifty-four published studies used this ratio (21 from a PubMed search from onset to 10/21/18 and 33 identified by the authors). To estimate a combined mean of the CLO/NCLO ratio in published studies, a PubMed search on 10/21/18 identified 422 articles leading to 19 included. The systematic review focused on 1) the combined analysis, 2) CYP1A2 activity, 3) clinical response, 4) cognition, and 5) renal function. Expert opinion: Our combined analysis provided a weighted mean CLO/NCLO ratio of 1.73 in 2,317 adult patients from 19 studies, but the range in …

OncologyAdultmedicine.medical_specialtyClozapine+NorclozapineRenal function030226 pharmacology & pharmacylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineGemfibrozilAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsClozapineClozapineRandomized Controlled Trials as TopicAdult patientsmedicine.diagnostic_testbusiness.industryGeneral MedicineTherapeutic drug monitoring030220 oncology & carcinogenesisDrug MonitoringbusinessRenal transportersmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue. This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-rela…

researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

researchProduct